Literature DB >> 1381355

Structure/function studies on vascular cell adhesion molecule-1.

B Pepinsky1, C Hession, L L Chen, P Moy, L Burkly, A Jakubowski, E P Chow, C Benjamin, G Chi-Rosso, S Luhowskyj.   

Abstract

Vascular cell adhesion molecule-1 (VCAM1) is a member of the immunoglobulin (Ig) superfamily which interacts with the integrin very late antigen-4 (VLA4). The VCAM1/VLA4 interaction mediates both adhesion and signal transduction and is thought to play an important role in inflammatory and immune responses in vivo. The major form of human VCAM1 contains seven extracellular Ig-like domains, with domain 1 designated as the most N-terminal. We have examined the relationship between human VCAM1 structure and function using a combination of domain truncation mutants and proteolytic fragmentation of recombinant soluble VCAM1. We have characterized two regions of VCAM1, localized to domains 4 and 5, which are highly sensitive to proteolytic cleavage, localized the epitope of the blocking monoclonal antibody 4B9 to domain 1, and found that domains 1-3 are sufficient for both its adhesive function and its ability to initiate T cell activation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381355

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Functional implication of the hydrolysis of platelet endothelial cell adhesion molecule 1 (CD31) by gingipains of Porphyromonas gingivalis for the pathology of periodontal disease.

Authors:  Peter L W Yun; Arthur A Decarlo; Cheryl C Chapple; Neil Hunter
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

2.  Genomic rearrangements on VCAM1, SELE, APEG1and AIF1 loci in atherosclerosis.

Authors:  D A Arvanitis; G A Flouris; D A Spandidos
Journal:  J Cell Mol Med       Date:  2005 Jan-Mar       Impact factor: 5.310

3.  The integrin VLA-4 supports tethering and rolling in flow on VCAM-1.

Authors:  R Alon; P D Kassner; M W Carr; E B Finger; M E Hemler; T A Springer
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

Review 4.  Vascular cell adhesion molecule-1 expression and signaling during disease: regulation by reactive oxygen species and antioxidants.

Authors:  Joan M Cook-Mills; Michelle E Marchese; Hiam Abdala-Valencia
Journal:  Antioxid Redox Signal       Date:  2011-05-11       Impact factor: 8.401

5.  The C-C chemokine receptor CCR3 participates in stimulation of eosinophil arrest on inflammatory endothelium in shear flow.

Authors:  J Kitayama; C R Mackay; P D Ponath; T A Springer
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

Review 6.  Alpha 4-integrin-dependent emigration of monocytes.

Authors:  H E Chuluyan; A C Issekutz
Journal:  Springer Semin Immunopathol       Date:  1995

7.  Sequential regulation of alpha 4 beta 1 and alpha 5 beta 1 integrin avidity by CC chemokines in monocytes: implications for transendothelial chemotaxis.

Authors:  C Weber; R Alon; B Moser; T A Springer
Journal:  J Cell Biol       Date:  1996-08       Impact factor: 10.539

8.  Differential regulation of beta 1 and beta 2 integrin avidity by chemoattractants in eosinophils.

Authors:  C Weber; J Kitayama; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

9.  Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor.

Authors:  James R Vasselli; Joanna H Shih; Shuba R Iyengar; Jodi Maranchie; Joseph Riss; Robert Worrell; Carlos Torres-Cabala; Ray Tabios; Andra Mariotti; Robert Stearman; Maria Merino; McClellan M Walther; Richard Simon; Richard D Klausner; W Marston Linehan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-30       Impact factor: 11.205

Review 10.  Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma.

Authors:  Steven R Barthel; Mats W Johansson; Dawn M McNamee; Deane F Mosher
Journal:  J Leukoc Biol       Date:  2007-10-10       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.